Thank you, Minister.
Mr. Chair, I would indicate, in response, that Health Canada—as the minister has indicated—continues to consult and engage the provinces, territories and stakeholders. With that, we will be able to define the path forward on this work on drugs to support Canadians with rare diseases. That would allow the funding to move forward and be considered in a subsequent estimate.